ARTICLE | Clinical News
GA Depot: Phase IIa started
January 5, 2015 8:00 AM UTC
Mapi-Pharma began an open-label, Israeli Phase IIa trial to evaluate once-monthly 80 mg intramuscular GA Depot for 1 year in about 20 patients previously treated with once-daily Copaxone glatiramer a...